Literature DB >> 27550853

Pancreatic cancer: Promise of doublet chemotherapy.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27550853     DOI： 10.1038/nrclinonc.2016.138

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.

Authors:  Lauren M Postlewait; Cecilia G Ethun; David A Kooby; Juan M Sarmiento; Zhengjia Chen; Charles A Staley; Edith Brutcher; Volkan Adsay; Bassel El-Rayes; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2016-08-08       Impact factor: 3.454
  1 in total
  2 in total

1.  miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis.

Authors:  Rui-Meng Yang; Ming Zhan; Sun-Wang Xu; Man-Mei Long; Lin-Hua Yang; Wei Chen; Shuai Huang; Qiang Liu; Jun Zhou; Jun Zhu; Jian Wang
Journal:  Cell Death Dis       Date:  2017-10-19       Impact factor: 8.469

2.  Blockade of integrin α3 attenuates human pancreatic cancer via inhibition of EGFR signalling.

Authors:  Jungwhoi Lee; Jungsul Lee; Chulhee Choi; Jae Hoon Kim
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.